Search - tctmd.com

Displaying 61 - 80 of 119

Sort: Relevancy | Date

News Conference News TCT 2015

Absorb BVS Matches Xience V in Chinese Patients

Todd Neale

October 12, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Presenter: Stephen G. Ellis, John A. Ormiston, Gregg W. Stone

October 11, 2015

News Conference News TCT 2015

Novel Devices Present New Treatment Options for STEMI

Yael L. Maxwell

October 11, 2015

Presentation TCT 2014

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Presenter: Kazushige Kadota

September 16, 2014

Presentation TCT 2014

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Presenter: Krishnankutty Sudhir

September 16, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

September 15, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

News Conference News TCT 2014

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

September 14, 2014

News Conference News TCT 2014

COMPARE II: STEMI Patients See Strong Results with Both BES and EES

September 14, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

News Conference News TCT 2014

ABSORB EXTEND: BVS Safe Out to 3 Years

September 14, 2014

News Conference News TCT 2014

COMPARE II: BES, EES Show Similar Outcomes at Three Years

September 13, 2014

News Conference News TCT 2013

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

October 30, 2013

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation TCT 2013

TCT-21. Prognosis of Clinical Outcomes in Chinese Patients Receiving XIENCE V Everolimus-Eluting Stent with Baseline and Residual Syntax Score: One-Year Results from the...

Presenter: Yuejin Yang

October 29, 2013

Presentation TCT 2013

TCT-16. Incidence, mechanisms and outcome of longitudinal stent deformation (LSD) associated with Element, Resolute, Biomatrix and Xience stents: angiographic and case-by-case...

Presenter: Samer Arnous

October 29, 2013

Presentation TCT 2013

Long-term Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold versus Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model

Presenter: Fumiyuki Otsuka

October 29, 2013

News Conference News TCT 2013

State of the Stent: PCI Future Intact Despite Costs, Sociopolitical Factors

October 29, 2013

Presentation TCT 2013

From Xience V to Prime to Xpedition: Stent Design Evolution and Clinical Trial Results (SPIRIT and Others)

Presenter: James Hermiller Jr

October 28, 2013

Advertisement

Absorb BVS Matches Xience V in Chinese Patients

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Novel Devices Present New Treatment Options for STEMI

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

COMPARE II: STEMI Patients See Strong Results with Both BES and EES

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

ABSORB EXTEND: BVS Safe Out to 3 Years

COMPARE II: BES, EES Show Similar Outcomes at Three Years

LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD

Innovation in Intervention: Perspectives from Industry

TCT-21. Prognosis of Clinical Outcomes in Chinese Patients Receiving XIENCE V Everolimus-Eluting Stent with Baseline and Residual Syntax Score: One-Year Results from the...

TCT-16. Incidence, mechanisms and outcome of longitudinal stent deformation (LSD) associated with Element, Resolute, Biomatrix and Xience stents: angiographic and case-by-case...

Long-term Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold versus Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model

State of the Stent: PCI Future Intact Despite Costs, Sociopolitical Factors

From Xience V to Prime to Xpedition: Stent Design Evolution and Clinical Trial Results (SPIRIT and Others)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content